Akihiko Shimomura, MD, PhD, Department of Breast and Medical Oncology, Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan, discusses the HERB TEA trial (JCOG1607) in patients with HER2-positive breast cancer.
Akihiko Shimomura, MD, PhD
Advertisement
Articles by Akihiko Shimomura, MD, PhD
Advertisement
Latest Updated Articles
Dr. Shimomura Discusses the HERB TEA Study in HER2+ Breast CancerNovember 12th 2018
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Sacituzumab Govitecan Monotherapy and In Combination With Pembrolizumab in Frontline TNBC
2
Dr Tolaney on the FDA Approval of First-Line Sacituzumab Govitecan Plus Pembrolizumab for TNBC
3
Introduction and Frontline Treatment Options for EGFR-Mutated NSCLC
4
Daratumumab Retreatment Displays Activity in Relapsed Myeloma Following Continuous Frontline Therapy
5